MedPharm Licenses Its MedSpray® Technology to Virpax
June 21, 2018
MedPharm Licenses Its MedSpray® ‘Patch-in-a-Can’ Technology to Virpax Pharmaceuticals for Non-Opioid Pain Management Products
MedPharm, the world leader in topical and transdermal development, licensed its unique MedSpray® technology to Virpax Pharmaceuticals (“Virpax”), a company based in Pennsylvania, US that is specialising in developing pharmaceutical products for pain management by using new drug delivery systems. MedSpray is covered by worldwide patents and delivers transdermal patch technology in a metered-dose aerosol spray. The thin film patch created on the skin or mucosal membrane has been demonstrated in clinical trials to provide long-lasting efficacy for patients.
MedPharm is now well-established as the leader in dermatological, nail, eye, airway, mucosal membrane and transdermal product development. Over the last 20 years, MedPharm has built a worldwide reputation for helping clients navigate the complex route to successful development of its pharmaceutical products. In parallel with fees for service work, MedPharm is constantly looking for opportunities to develop new formulation and drug delivery technologies such as MedSpray which enhances clients’ products, provides clinical benefits for patients and meets the increasingly stringent requirements of regulatory authorities.
MedPharm is working closely with Virpax to develop DSF100 (NSAID spray film 1.3%), an investigational spray film designed to deliver an NSAID transdermally via a metered-dose spray. The delivery system features a high level of adhesiveness, accessibility and skin drying. Virpax filed a pre-IND meeting request with the U.S. Food and Drug Administration (FDA) and it was granted on May 18, 2018.
“MedSpray’s unique dosing offers clients the opportunity to differentiate their product and potentially achieve premium pricing for extended effects,” said Dr. Jeremy Drummond, MedPharm’s SVP of Business Development. “We are looking forward to partnering with Virpax to bring products with our MedSpray technology to market.”
“We believe there is an opportunity to explore the development of non-opioid transdermal pain treatments that improve on existing gel and patch products, for which adhesion and accessibility can be a challenge,” said Anthony Mack, CEO of Virpax. “We believe that the ‘Patch-in-a-Can’ technology offers a promising delivery system and we are excited to be collaborating with a world leader like MedPharm.”
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established R&D centres in the USA and UK and has its global HQ in Guildford, UK.
Virpax develops branded pharmaceutical products for pain management by using cutting-edge technology to enhance patients’ quality of life, all while creating value for its investors and partners. The company is focused on becoming a global leader in pain management by developing and delivering innovative pharmaceutical products to its customers. Virpax is based in Malvern, PA, USA. For more information visit www.virpaxpharma.com.